HER2低表达乳腺癌的临床研究进展  

Clinical research progress of breast cancer with low HER2 expression

作　　者：吴蕊玥 朱凯丽 杨景茹(综述) 令晓玲(审校)[1,2] WU Ruiyue;ZHU Kaili;YANG Jingru;LING Xiaoling(First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Oncology,The First Hospital of Lanzhou University)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院肿瘤科

出　　处：《实用肿瘤学杂志》2022年第6期570-575,共6页Practical Oncology Journal

基　　金：甘肃省自然科学基金(编号:22JR5RA909)。

摘　　要：乳腺癌是全球发病率最高的恶性肿瘤,严重影响女性的健康。人表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)作为乳腺癌重要的治疗靶点,对应的靶向治疗改善了此类患者的预后。在既往的诊治过程中,HER2低表达乳腺癌被归类为HER2阴性乳腺癌的范畴。随着研究的不断深入,发现HER2低表达乳腺癌患者在临床病理、分子生物学特征和生存预后等方面具有一定差异,并且难以从传统的抗HER2治疗中获益。多项研究探索了抗体药物偶联物(Antibody-drug conjugates, ADC)以及其他新型药物在HER2低表达乳腺癌中的疗效及安全性。本文将针对HER2低表达乳腺癌相关研究进展进行综述。Breast cancer is the malignant tumor with the highest incidence in the world, which seriously affects women′s health.As an important therapeutic target for breast cancer, human epidermal growth factor receptor 2(HER2)has improved the prognosis of these patients.In the past diagnosis and treatment process, breast cancer with low HER2 expression was classified as HER2 negative breast cancer.With the deepening research, it is found that breast cancer patients with HER2 low expression have some differences in clinicopathological and molecular biological characteristics, as well as survival prognosis, and are difficult to benefit from traditional anti-HER2 therapy.Several studies have explored the efficacy and safety of antibody-drug conjugates(ADCs)and other new drugs in breast cancer with low HER2 expression.This article will review the research progress of breast cancer with low HER2 expression.

关 键 词：乳腺癌 人表皮生长因子受体2 低表达 研究进展 

分 类 号：R737.9[医药卫生—肿瘤]